University of Houston (K.R., E.T., M.A.B.), College of Optometry, Houston, TX; PharmaLogic Development, Inc (G.D.N.), San Rafael, CA; and Department of Ophthalmology & Vision Sciences (G.D.N.), School of Medicine, University of California, Davis, CA.
Address correspondence to Mark A. Bullimore, M.C.Optom., Ph.D., 356 Ridgeview Lane, Boulder, CO 80302; e-mail: [email protected]
K. Richdale receives research funding from Alcon and Vyluma and is a consultant for CooperVision, Euclid, Johnson & Johnson Vision, Novartis, Paragon Vision Sciences, SightGlass, and Sydnexis. E. Tomiyama is a consultant for Paragon Vision Sciences. G. D. Novack Ph.D. consults with numerous pharmaceutical and medical device firms. M. A. Bullimore is a consultant for Alcon Research, CooperVision, CorneaGen, EssilorLuxottica, Eyenovia, Genentech, Johnson & Johnson Vision, Lentechs, Novartis, Oculus, Paragon Vision Sciences, and Vyluma and is the sole owner of Ridgevue Publishing, LLC, and Ridgevue Vision LLC.
The study was supported by an unrestricted grant from Vyluma.